Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atovaquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.82 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atovaquone SCHEMBL21694 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL20769805 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL1542719 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL9975142 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL29559044 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL8848607 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL8851283 | 0.90 | MAPT (0.67) | MAPTKMT2AMEN1LMNAUSP2 | |
| SCHEMBL21695 | 0.90 | MAPT (1.00) | MAPTKMT2AMEN1LMNAUSP2 | |
| SCHEMBL1649508 | 0.90 | MAPT (1.00) | MAPTKMT2AMEN1LMNAUSP2 | |
| SCHEMBL28082527 | 0.89 | MAPT (0.73) | MAPTKMT2AMEN1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111793-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2023-04-13 | — | — | US | claimed |
| CN-114569552-A | Anti-malarial compositions and uses thereof | 斯克利普斯研究院 | 2022-06-03 | — | — | CN | claimed |
| US-20210179524-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2021-06-17 | — | — | US | claimed |
| US-10947176-B2 | Antimalarial compositions and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-16 | — | — | US | claimed |
| US-20190202766-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2019-07-04 | — | — | US | claimed |
| US-10130590-B2 | Methods of treating cancer with atovaquone-related compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-11-20 | — | — | US | claimed |
| US-9169232-B2 | 3-(5-methyl-2-oxo-l, 3-dioxol-4-yl) methyloxy-2-trans-[(4-chloro phenyl) cyclohexyl][1,4]naphthaquinone-atovaquone prodrug | ALKEM LABORATORIES LIMITED (IN) | 2015-10-27 | — | — | US | claimed |
| US-20140343297-A1 | 3-(5-METHYL-2-OXO-L, 3-DIOXOL-4-YL) METHYLOXY-2- TRANS-[(4-CHLORO PHENYL) CYCLOHEXYL][1,4]NAPHTHAQUINONE-ATOVAQUONE PRODRUG | ALKEM LABORATORIES LTD. (IN) | 2014-11-20 | — | — | US | claimed |
| CN-103570520-A | Benzoquinones compound, preparation method and application thereof | SHANDONG LUKANG SHELILE PHARMACEUTICAL CO LTD | 2014-02-12 | — | — | CN | claimed |
| CN-103570521-A | Preparation method of atovaquone | SHANDONG LUKANG SHELILE PHARMACEUTICAL CO LTD | 2014-02-12 | — | — | CN | claimed |
| WO-1992013527-A1 | WATER-DISPERSIBLE TABLETS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-08-20 | — | — | WO | claimed |
| EP-0496729-A1 | MEDICAMENT FOR THE TREATMENT OF CRYPTOSPORIDIOSIS. | WELLCOME FOUND (GB) | 1992-08-05 | — | — | EP | claimed |
| US-5053418-A | Synergistic mixture of 2-(4,-(4-chlorophenyl)cyclohexyl)3-hydr oxy-1,4 napthoquinone and 3,5-dichloro-2,6 dichloropyridinol | BURROUGHS WELLCOME CO. (US) | 1991-10-01 | — | — | US | claimed |
| EP-0445141-A1 | MEDICAMENTS FOR THE TREATMENT OF TOXOPLASMOSIS. | WELLCOME FOUND (GB) | 1991-09-11 | — | — | EP | claimed |
| EP-0123239-B1 | IMPROVEMENTS IN OR RELATING TO ANTIPROTOZOAL AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-09-11 | — | — | EP | claimed |
| WO-1991005550-A1 | MEDICAMENT FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-05-02 | — | — | WO | claimed |
| WO-1991004021-A1 | MEDICAMENTS FOR THE TREATMENT OF TOXOPLASMOSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-04 | — | — | WO | claimed |
| US-4981874-A | PREVENTING PNEUMOXYSTIS PNEUMONIA IN AIDS PATIENTS | LATTER VICTORIA S (GB) | 1991-01-01 | — | — | US | claimed |
| EP-0401875-A2 | Improvements in or relating to antiprotozoal agents | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-12 | — | — | EP | claimed |
| EP-0362996-A2 | Naphthoquinones for the treatment and prophylaxis of pneumocystis carinii infections | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343297-A1 | 3-(5-METHYL-2-OXO-L, 3-DIOXOL-4-YL) METHYLOXY-2- TRANS-[(4-CHLORO PHENYL) CYCLOHEXYL][1,4]NAPHTHAQUINONE-ATOVAQUONE PRODRUG | DHPS, ATIC, DHODH | MAPT 2378/4885KMT2A 1517/4885MEN1 3297/4885 |
| US-20210179524-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | GPX4, MPO, G6PD | MAPT 1240/4885KMT2A 2654/4885MEN1 1766/4885 |
| US-10947176-B2 | Antimalarial compositions and uses thereof | GPX4, MPO, G6PD | MAPT 1240/4885KMT2A 2654/4885MEN1 1766/4885 |
| US-20230111793-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | GPX4, MPO, G6PD | MAPT 1240/4885KMT2A 2654/4885MEN1 1766/4885 |
| US-10130590-B2 | Methods of treating cancer with atovaquone-related compounds | MTOR, SDHA, RPTOR | MAPT 3964/4885KMT2A 2091/4885MEN1 2920/4885 |
| US-20190202766-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | GPX4, MPO, G6PD | MAPT 1240/4885KMT2A 2654/4885MEN1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.